Archetype uses an AI‑native generative chemogenomics platform to virtually screen billions of drug‑like molecules against large patient clinicogenomic datasets, predicting clinical outcomes and trial success. By linking molecular designs to real‑world patient data, it enables pharmaceutical and biotech companies to prioritize pre‑lead candidates, identify repurposing opportunities, and accelerate early‑stage drug discovery across multiple disease areas.
Funding
Funding not disclosed
Founders
Product
Problem
Drug discovery traditionally relies on low‑throughput experimental screening and limited patient data, leading to high failure rates, long timelines, and costly clinical trials.
Solution
Archetype leverages generative chemogenomics and large‑scale patient clinicogenomic datasets to perform massive virtual phenotypic screening of billions of drug‑like molecules. The AI‑native platform models disease‑drug dynamics across multiple biological states, enabling end‑to‑end in silico evaluation of candidate compounds against real‑world clinical outcomes. By linking molecular designs directly to patient cohorts, Archetype can predict trial success, identify repurposing opportunities, and prioritize pre‑lead molecules for diseases such as metastatic castration‑resistant prostate cancer, early‑stage lung adenocarcinoma, metastatic melanoma, and idiopathic pulmonary fibrosis. This approach accelerates discovery, reduces reliance on costly wet‑lab experiments, and aligns early drug candidates with clinically relevant biomarkers.
Target Audience
Primary customers are pharmaceutical companies, biotech firms, and contract research organizations seeking AI‑enhanced early‑stage drug discovery and target validation, particularly for oncology and fibrotic disease programs.
Features
- Generative chemogenomics engine that designs and optimizes billions of drug‑like structures in silico
- Virtual phenotypic screening using patient clinicogenomic and real‑world evidence data to predict clinical outcomes
- Multi‑target, systems‑biology readouts that capture complex disease‑drug interactions beyond single‑target models
- AI‑driven prediction of trial success and drug repurposing potential across multiple therapeutic areas
- Integrated biomarker program linking molecular candidates to patient cohorts for built‑in clinical relevance
- Cloud‑based analytics pipeline that automates chemist‑like modifications and ranks candidates for downstream validation